Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase NA 1

Status

Recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

NET 7Endocrine 7CNS 2Gastrointestinal 1Dermatologic 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 2Paraganglioma 2Gastro-enteropancreatic neuroendocrine tumor 2Vipoma 1Thymus Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Insulinoma 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
170 enrolled
EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Lund University Hospital

Phase 3 Recruiting
300 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06045260 2024-08-13

LUFOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
100 enrolled
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Withdrawn
CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04194125 2020-11-04

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

University of Warmia and Mazury

Phase 2 Unknown
25 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡